IGC Quote, Financials, Valuation and Earnings

Lineage Cell Therapeutics has a net margin of -711.67% compared to IGC Pharma's net margin of -275.57%. IGC Pharma's return on equity of -116.24% beat Lineage Cell Therapeutics's return on equity of -22.68%.

IGC Pharma has a consensus price target of $3.88, signalling upside risk potential of 1083.21%. On the other hand Lineage Cell Therapeutics has an analysts' consensus of $3.92 which suggests that it could grow by 473.54%. Given that IGC Pharma has higher upside potential than Lineage Cell Therapeutics, analysts believe IGC Pharma is more attractive than Lineage Cell Therapeutics.

IGC Pharma has a beta of 1.503, which suggesting that the stock is 50.252% more volatile than S&P 500. In comparison Lineage Cell Therapeutics has a beta of 1.414, suggesting its more volatile than the S&P 500 by 41.436%.

IGC Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lineage Cell Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IGC Pharma pays -- of its earnings as a dividend. Lineage Cell Therapeutics pays out -- of its earnings as a dividend.

IGC Pharma quarterly revenues are $257K, which are smaller than Lineage Cell Therapeutics quarterly revenues of $1.5M. IGC Pharma's net income of -$1.8M is higher than Lineage Cell Therapeutics's net income of -$4.1M. Notably, IGC Pharma's price-to-earnings ratio is -- while Lineage Cell Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IGC Pharma is 19.26x versus 15.08x for Lineage Cell Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -711.67% compared to IGC Pharma's net margin of -49.65%. IGC Pharma's return on equity of -116.24% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

IGC Pharma has a consensus price target of $3.88, signalling upside risk potential of 1083.21%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 50.23%. Given that IGC Pharma has higher upside potential than NovaBay Pharmaceuticals, analysts believe IGC Pharma is more attractive than NovaBay Pharmaceuticals.

IGC Pharma has a beta of 1.503, which suggesting that the stock is 50.252% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.419, suggesting its less volatile than the S&P 500 by 58.08%.

IGC Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IGC Pharma pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

IGC Pharma quarterly revenues are $257K, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. IGC Pharma's net income of -$1.8M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, IGC Pharma's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IGC Pharma is 19.26x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Protalix BioTherapeutics has a net margin of -711.67% compared to IGC Pharma's net margin of -35.79%. IGC Pharma's return on equity of -116.24% beat Protalix BioTherapeutics's return on equity of 10.9%.

IGC Pharma has a consensus price target of $3.88, signalling upside risk potential of 1083.21%. On the other hand Protalix BioTherapeutics has an analysts' consensus of $14.00 which suggests that it could grow by 797.44%. Given that IGC Pharma has higher upside potential than Protalix BioTherapeutics, analysts believe IGC Pharma is more attractive than Protalix BioTherapeutics.

IGC Pharma has a beta of 1.503, which suggesting that the stock is 50.252% more volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of -0.048, suggesting its less volatile than the S&P 500 by 104.824%.

IGC Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IGC Pharma pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

IGC Pharma quarterly revenues are $257K, which are smaller than Protalix BioTherapeutics quarterly revenues of $10.1M. IGC Pharma's net income of -$1.8M is higher than Protalix BioTherapeutics's net income of -$3.6M. Notably, IGC Pharma's price-to-earnings ratio is -- while Protalix BioTherapeutics's PE ratio is 39.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IGC Pharma is 19.26x versus 2.19x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -711.67% compared to IGC Pharma's net margin of --. IGC Pharma's return on equity of -116.24% beat Theriva Biologics's return on equity of --.

IGC Pharma has a consensus price target of $3.88, signalling upside risk potential of 1083.21%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1527.91%. Given that Theriva Biologics has higher upside potential than IGC Pharma, analysts believe Theriva Biologics is more attractive than IGC Pharma.

IGC Pharma has a beta of 1.503, which suggesting that the stock is 50.252% more volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.144, suggesting its more volatile than the S&P 500 by 14.418%.

IGC Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IGC Pharma pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

IGC Pharma quarterly revenues are $257K, which are larger than Theriva Biologics quarterly revenues of --. IGC Pharma's net income of -$1.8M is higher than Theriva Biologics's net income of -$4.3M. Notably, IGC Pharma's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IGC Pharma is 19.26x versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.